You just read:

INVOKANA® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program

News provided by

Janssen Pharmaceutical Companies

Jun 12, 2017, 18:23 ET